Brought to you by:
Registry data show greater clot chronicity on post-procedure inspection than initially predicted
Nearly half of patients deemed pre-procedurally to be suffering an acute case of deep vein thrombosis (DVT) turned out to have a “much more” chronic classification of the condition following intraoperative imaging and thrombus inspection post-procedure, an interim analysis from…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
‘TCAR yields high technical success with an extraordinarily low stroke and death rate at one year’
Outcomes in a cohort of patients who consented to one year of follow-up after transcarotid revascularization (TCAR) treatment for carotid stenosis in the ROADSTER 2 trial showed a 97.4% rate of technical success, no incidences of ipsilateral stroke and a…
Physicians, industry urged to tackle multifactorial stroke risk following thoracic endovascular procedures
As evidence builds on the importance of reducing the risk of stroke by removing residual air prior to thoracic endovascular aortic repair (TEVAR) procedures, the onus will be on surgeons and device manufacturers to minimize this risk, attendees of CX…
One-year results show ‘superior’ primary patency rate for Eluvia DES compared to bare metal stents
One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia drug-eluting stent (DES) system (Boston Scientific) compared to self-expanding bare metal stents for the treatment of…
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24…
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in…
Vascular surgeons found to ask twice as many closed- versus open-ended questions in patient encounters
Patients reported they mostly felt their provider was adequate in terms of engaging in shared decision-making during asymptomatic vascular consults, according to a qualitative analysis carried out at the University of Iowa in Iowa City. Furthermore, vascular surgery compared favorably…
Study detects no difference in adverse outcomes from balloon dilatation strategy used during TCAR
Avoiding a strategy of post-stent balloon dilation during transcarotid artery revascularization (TCAR) may be unnecessary—a “contradistinction” to results shown in conventional transfemoral carotid artery stenting, new research has shown. Jones Thomas, MD, an integrated vascular surgery resident at University Hospitals…
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session…